Sulfuretin

Sulfuretin

SCHEMBL634007

O=C1C(=Cc2ccc(O)c(O)c2)Oc2cc(O)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 1.00
KMT2A Q03164 8/20 1.00
RECQL P46063 4/20 1.00
STK17B O94768 3/20 1.00
MAOA P21397 3/20 1.00
KDM4E B2RXH2 2/20 1.00
NPC1 O15118 2/20 1.00
GAA P10253 2/20 1.00
MAPT P10636 2/20 1.00
AURKA O14965 2/20 1.00
GSK3B P49841 2/20 1.00
CDK5 Q00535 2/20 1.00
CDK5R1 Q15078 2/20 1.00
PSMD14 O00487 1/20 1.00
DAPK3 O43293 1/20 1.00
JAK2 O60674 1/20 1.00
ALPL P05186 1/20 1.00
ALPI P09923 1/20 1.00
ALPG P10696 1/20 1.00
CDK4 P11802 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuretin SCHEMBL30214394 1.00 MEN1 (1.00) MEN1KMT2ARECQLSTK17BMAOA
Sulfuretin SCHEMBL30214408 1.00 MEN1 (1.00) MEN1KMT2ARECQLSTK17BMAOA
Sulfuretin SCHEMBL8346701 1.00 MEN1 (1.00) MEN1KMT2ARECQLSTK17BMAOA
Sulfuretin SCHEMBL634006 1.00 MEN1 (1.00) MEN1KMT2ARECQLSTK17BMAOA
Sulfuretin SCHEMBL29545005 1.00 MEN1 (1.00) MEN1KMT2ARECQLSTK17BMAOA
SCHEMBL30337058 0.89 STK17B (1.00) MEN1KMT2ARECQLSTK17BMAOA
SCHEMBL5707753 0.88 TYR (1.00) MEN1KMT2ARECQLSTK17BMAOA
SCHEMBL29435856 0.88 TYR (1.00) MEN1KMT2ARECQLSTK17BMAOA
SCHEMBL30214422 0.88 TYR (1.00) MEN1KMT2ARECQLSTK17BMAOA
SCHEMBL6964950 0.88 MEN1 (0.78) MEN1KMT2ARECQLSTK17BMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO claimed
US-12390418-B2 Biphasic compositions comprising one or both of carbonate and phosphate Natural Extraction Systems, LLC (US) 2025-08-19 US disclosed
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 US disclosed
CN-116023358-B Method for extracting genistein, fisetin and thioflavin from cotinus coggygria 四川太时生物科技集团有限公司 2024-07-09 CN disclosed
CN-116023358-A Method for extracting genistein, fisetin and thioflavin from cotinus coggygria 四川太时生物科技集团有限公司 2023-04-28 CN disclosed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO disclosed
CN-115677635-A Aurone derivative and application thereof 中国科学院新疆理化技术研究所 2023-02-03 CN disclosed
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO disclosed
EP-1888174-B1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER (US) 2012-02-22 EP disclosed
US-7629006-B2 Process for preparing extract from rhus verniciflua and pharmaceutical composition containing the same AZI Company, Ltd (KR) 2009-12-08 US disclosed
US-7629006-B2 Process for preparing extract from rhus verniciflua and pharmaceutical composition containing the same AZI Company, Ltd (KR) 2009-12-08 US disclosed
US-20080233223-A1 Process For Preparing Extract From Rhus Verniciflua and Pharmaceutical Composition Containing the Same AZI CO., LTD. (KR) 2008-09-25 US disclosed
US-20080233223-A1 Process For Preparing Extract From Rhus Verniciflua and Pharmaceutical Composition Containing the Same AZI CO., LTD. (KR) 2008-09-25 US disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 MEN1 3326/4885KMT2A 4014/4885RECQL 114/4885
US-20080233223-A1 Process For Preparing Extract From Rhus Verniciflua and Pharmaceutical Composition Containing the Same CMA1, HRH2, DCXR MEN1 4880/4885KMT2A 512/4885RECQL 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.